Array BioPharma (NASDAQ: ARRY) reported a narrower-than-expected loss in the third quarter of 2019, sending its shares up 0.5% during pre-market trading
Earnings: Array BioPharma reports upbeat Q3 results
Categories
Health Care
Mylan reports Q1 earnings beat on weak revenues, confirms 2019 outlook
Mylan’s (MYL) stock plunged about 5% in the pre-market trading after the company’s revenues failed to meet estimates. However, adjusted earnings surpassed
Allergan beats estimates on Q1 results, raises full-year guidance
Allergan plc (NYSE: AGN) topped market forecasts on revenue and earnings for the first quarter of 2019. Despite the beat, shares fell
Regeneron Q1 profit falls 4%, misses estimates
Regeneron Pharmaceuticals (NASDAQ: REGN) reported a 4% decline in earnings for the first quarter of 2019 due to higher costs and expenses.
GW Pharmaceuticals’ stock climbs on Q1 results beat
Medical marijuana company GW Pharmaceuticals (NASDAQ: GWPH) beat market expectations on revenue and earnings for the first quarter of 2019, sending shares
Bausch Health’s stock gains on improved outlook
Bausch Health Companies Inc. (NYSE: BHC) missed revenue expectations for the first quarter of 2019 and did not provide a number for
Earnings preview: What to expect when Allergan reports Q1 2019 earnings results
Allergan plc (NYSE: AGN) is scheduled to report earnings results for the first quarter of 2019 on Tuesday, May 7, before market
Earnings preview: Regeneron set for a blockbuster quarter amid robust sales
Regeneron Pharmaceuticals (Nasdaq: REGN) will be reporting earnings for the first quarter Tuesday before the opening bell. Market watchers are of the
Immunogen Inc (NASDAQ: IMGN) Q1 2019 Earnings Call Transcript
Immunogen Inc (IMGN) Q1 2019 earnings call dated May 03, 2019 Corporate Participants: Sarah Kiely -- Director of Investor Relations Mark Enyedy -- President and Chief Executive Officer
Wall Street expects a revenue surge from GW Pharmaceuticals in Q1
Medical marijuana company GW Pharmaceuticals (NASDAQ: GWPH) is scheduled to report first-quarter 2019 earnings results on May 6, Monday, after the closing
Novo Nordisk’s (NYSE: NVO) profit declines 3% in Q1 2019
Denmark-based healthcare giant Novo Nordisk (NYSE: NVO, CPH: NOVO-B) reported its first quarter 2019 results today. Novo Nordisk's profit dropped 3%, while
ImmunoGen reports 57% decline in Q1 revenue
ImmunoGen Inc (NASDAQ: IMGN) on Friday reported weaker-than-expected top line in Q1, as the biotech firm continued to burn money on research
Gilead Sciences tops Q1 earnings estimate, reiterates full-year outlook
Shares of Gilead Sciences (NASDAQ: GILD) gained 1.2% after the biotechnology firm reported first-quarter earnings of $1.76 per share, surpassing the street
Novavax beats Q1 revenue estimates while earnings come in line
Novavax Inc. (NASDAQ: NVAX) topped market estimates on revenue for the first quarter of 2019 while earnings matched expectations. Analysts had forecasted
ImmunoGen is cheap ahead of Q1 earnings, but is it worth?
ImmunoGen Inc (NASDAQ: IMGN) is one of the worst performing stocks out there, losing about 78% of its value over the course
Earnings: Cigna posts upbeat Q1 results
Cigna Corp. (NYSE: CI) reported a 50% jump in earnings for the first quarter of 2019 as continued strong business growth in
Teva Pharma sinks on Q1 revenue miss amid generic competition; earnings beat
Drugmaker Teva Pharmaceutical (NYSE: TEVA) reported a decline in first-quarter adjusted earnings, owing to a 15% fall in revenues as the company
Abiomed’s stock plunges to new 52-week low on Q4 revenue miss
Abiomed’s (NASDAQ: ABMD) stock plunged about 17% in the pre-market trading as the company failed to meet top-line estimates. It touched a
Exelixis tops Q1 earnings and revenue estimates
Exelixis Inc. (NASDAQ: EXEL) surpassed Q1 earnings and revenue projections. The company reported earnings of $0.27 per share on revenue of $215.5
Acorda Therapeutics stock sinks to 13-year low
Acorda Therapeutics (NASDAQ: ACOR) stock tumbled to a 13-year low of $10.02 on Wednesday as investors remained concerned about the company's future
Novavax Q1 earnings preview: Future plans on ResVax and NanoFlu will be the key focus points
Novavax Inc (NASDAQ: NVAX) is slated to report its first quarter 2019 earnings results after market closes on Thursday. Novavax stock, which